Loading…
Gufic Biosciences (GUFICBIO)₹474.35+8.72%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Gufic Biosciences reported sales of ₹262 Cr, up 16.6% from Jun 2025, and net profit of ₹22.05 Cr, up 69.1% year on year. For the year to Mar 2026, sales were ₹948 Cr and net profit ₹64.19 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 216 | 203 | 196 | 204 | 205 | 209 | 206 | 225 | 238 | 232 | 253 | 262 |
| Expenses | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 |
| Operating Profit | 39.07 | 36.09 | 34.05 | 36.06 | 39.06 | 34.08 | 26.05 | 33.10 | 38.06 | 33.07 | 47.13 | 47.11 |
| OPM % | 18.0% | 18.0% | 18.0% | 18.0% | 19.0% | 16.0% | 13.0% | 15.0% | 16.0% | 14.0% | 19.0% | 18.0% |
| Other Income | 0.00 | 0.00 | 1.01 | 1.01 | 0.00 | 2.01 | 0.00 | 1.01 | 2.01 | 1.01 | −1.01 | 0.00 |
| Interest | 4.01 | 2.99 | 3.99 | 4.99 | 4.99 | 5.01 | 7.99 | 9.01 | 10.01 | 8.01 | 9.01 | 8.99 |
| Depreciation | 4.01 | 4.01 | 4.01 | 4.01 | 4.01 | 5.01 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 |
| Profit before tax | 30.98 | 29.99 | 26.98 | 28.01 | 28.98 | 26.01 | 11.01 | 17.01 | 23.01 | 17.99 | 29.01 | 29.99 |
| Tax % | 25.1% | 25.1% | 26.1% | 26.0% | 26.0% | 26.0% | 27.0% | 24.1% | 26.0% | 30.0% | 24.1% | 26.0% |
| Net Profit | 23.05 | 22.06 | 20.04 | 21.06 | 22.04 | 19.04 | 8.02 | 13.04 | 17.04 | 12.03 | 22.07 | 22.05 |
| EPS (Rs) | 2.38 | 2.23 | 1.99 | 2.07 | 2.18 | 1.92 | 0.76 | 1.29 | 1.69 | 1.23 | 2.19 | 2.21 |
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 810 | 823 | 948 | 985 |
| Expenses | 658 | 685 | 794 | 817 |
| Operating Profit | 150 | 136 | 151 | 165 |
| OPM % | 19.0% | 17.0% | 16.0% | 16.8% |
| Other Income | 0.00 | 4.02 | 3.01 | 2.01 |
| Interest | 16.99 | 24.99 | 37.01 | 36.02 |
| Depreciation | 17.04 | 21.06 | 31.06 | 32.08 |
| Profit before tax | 116 | 94.04 | 87.02 | 100 |
| Tax % | 26.1% | 26.0% | 26.1% | — |
| Exceptional items | −1.99 | 0.00 | 0.00 | — |
| Net Profit | 86.16 | 70.18 | 64.19 | 73.19 |
| EPS (Rs) | 8.58 | 6.94 | 6.41 | 7.32 |
| Dividend payout % | 1.0% | 1.0% | 2.0% | — |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 9.98 | 9.97 | 9.97 |
| Reserves | 523 | 591 | 654 |
| Borrowings | 333 | 336 | 404 |
| Other Liabilities | 226 | 231 | 272 |
| Total Liabilities | 1,092 | 1,167 | 1,339 |
| Fixed Assets | 159 | 507 | 491 |
| CWIP | 308 | 22.03 | 22.04 |
| Investments | 2.01 | 2.01 | 2.01 |
| Other Assets | 623 | 637 | 824 |
| Inventories | 200 | 217 | 325 |
| Trade receivables | 330 | 315 | 297 |
| Cash & equivalents | 12.98 | 28.91 | 75.79 |
| Total Assets | 1,092 | 1,167 | 1,339 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from operating activity | −7.01 | 123 | 45.05 |
| Cash from investing activity | −102 | −70.75 | −30.89 |
| Cash from financing activity | 82.30 | −37.16 | 32.11 |
| Net cash flow | −27.01 | 14.99 | 46.03 |
| Capex | 113 | 75.57 | 31.20 |
| Free cash flow | −116 | 51.80 | 13.95 |
| CFO / OP % | 13.0% | 107.1% | 38.0% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor days | 150 | 141 | 116 |
| Inventory days | 187 | 210 | 280 |
| Days payable | 156 | 155 | 172 |
| Cash conversion cycle | 180 | 196 | 223 |
| Working capital days | 97 | 93 | 80 |
| ROCE % | — | 12.9% | 12.0% |
For the Jun 2026 quarter, Gufic Biosciences reported sales of ₹262 Cr, up 16.6% year on year and net profit of ₹22.05 Cr, up 69.1% year on year. The operating margin was 18.0%.
Gufic Biosciences' sales for the year to Mar 2026 were ₹948 Cr; over the last twelve months they were ₹985 Cr.
Net profit for the year to Mar 2026 was ₹64.19 Cr, and ₹73.19 Cr over the last twelve months. Earnings per share over the same trailing period were ₹7.32.
Gufic Biosciences reported borrowings of ₹404 Cr at Mar 2026, against cash and equivalents of ₹75.79 Cr.
Cash from operations was ₹45.05 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹13.95 Cr.